|
|
 | | | |
- close
- close
- close
- close
| |||||||||
ELN » Topics » We are subject to continuing potential product liability risks, which could cost us material amounts of money.This excerpt taken from the ELN 6-K filed Mar 30, 2009. We
are subject to continuing potential product liability risks,
which could cost us material amounts of money.
Risks relating to product liability claims are inherent in the
development, manufacturing and marketing of our products. Any
person who is injured while using one of our products, or
products that we are responsible for, may have a product
liability claim against us. Since we distribute and sell our
products to a wide number of end users, the risk of such claims
could be material. Persons who participate in clinical trials
involving our products may also bring product liability claims.
Excluding any self-insured arrangements, we currently do not
maintain product liability insurance for the first
$25.0 million of aggregate claims, but do maintain coverage
with our insurers for the next $200.0 million. Our
insurance coverage may not be sufficient to cover fully all
potential claims, nor can we guarantee the solvency of any of
our insurers.
If our claims experience results in higher rates, or if product
liability insurance otherwise becomes costlier because of
general economic, market or industry conditions, then we may not
be able to maintain product liability coverage on acceptable
terms. If sales of our products increase materially, or if we
add significant products to our portfolio, then we will require
increased coverage and may not be able to secure such coverage
at reasonable rates or terms.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. We are
subject to continuing potential product liability risks, which
could cost us material amounts of money.
Risks relating to product liability claims are inherent in the
development, manufacturing and marketing of our products. Any
person who is injured while using one of our products, or
products that we are responsible for, may have a product
liability claim against us. Since we distribute and sell our
products to a wide number of end users, the risk of such claims
could be material. Persons who participate in clinical trials
involving our products may also bring product liability claims.
Excluding any self-insured arrangements, we currently do not
maintain product liability insurance for the first
$25.0 million of aggregate claims, but do maintain coverage
with our insurers for the next $200.0 million. Our
insurance coverage may not be sufficient to cover fully all
potential claims, nor can we guarantee the solvency of any of
our insurers.
If our claims experience results in higher rates, or if product
liability insurance otherwise becomes costlier because of
general economic, market or industry conditions, then we may not
be able to maintain product liability coverage on acceptable
terms. If sales of our products increase materially, or if we
add significant products to our portfolio, then we will require
increased coverage and may not be able to secure such coverage
at reasonable rates or terms.
This excerpt taken from the ELN 6-K filed Mar 31, 2008. We
are subject to continuing potential product liability risks,
which could cost us material amounts of money.
Risks relating to product liability claims are inherent in the
development, manufacturing and marketing of our products. Any
person who is injured while using one of our products, or
products that we are responsible for, may have a product
liability claim against us. Since we distribute and sell our
products to a wide number of end users, the risk of such claims
could be material. Persons who participate in clinical trials
involving our products may also bring product liability claims.
Excluding any self-insured arrangements, we currently do not
maintain product liability insurance for the first
$25.0 million of aggregate claims, but do maintain coverage
for the next $175.0 million with our insurers. Our
insurance coverage may not be sufficient to cover fully all
potential claims, nor can we guarantee the solvency of any of
our insurers.
If our claims experience results in higher rates, or if product
liability insurance otherwise becomes costlier because of
general economic, market or industry conditions, then we may not
be able to maintain product liability coverage on acceptable
terms. If sales of our products increase materially, or if we
add significant products to our portfolio, then we will require
increased coverage and may not be able to secure such coverage
at reasonable rates or terms.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. We are
subject to continuing potential product liability risks, which
could cost us material amounts of money.
Risks relating to product liability claims are inherent in the
development, manufacturing and marketing of our products. Any
person who is injured while using one of our products, or
products that we are responsible for, may have a product
liability claim against us. Since we distribute and sell our
products to a wide number of end users, the risk of such claims
could be material. Persons who participate in clinical trials
involving our products may also bring product liability claims.
Excluding any self-insured arrangements, we currently do not
maintain product liability insurance for the first
$25.0 million of aggregate claims, but do maintain coverage
for the next $175.0 million with our insurers. Our
insurance coverage may not be sufficient to cover fully all
potential claims, nor can we guarantee the solvency of any of
our insurers.
If our claims experience results in higher rates, or if product
liability insurance otherwise becomes costlier because of
general economic, market or industry conditions, then we may not
be able to maintain product liability coverage on acceptable
terms. If sales of our products increase materially, or if we
add significant products to our portfolio, then we will require
increased coverage and may not be able to secure such coverage
at reasonable rates or terms.
| EXCERPTS ON THIS PAGE:
|
| |||||||
